Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Bone changes during and after treatment of childhood acute lymphoblastic leukaemia

Полный текст:


Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with a survival rate of 80%. Major complications of leukemia include osteoporosis that requires both a clinically significant fracture history and low bone mineral density (BMD). The present study aims to assess BMD among acute lymphoblastic leukemia patients and survivors using dual-energy x-ray absorptiometry and serum insulin growth factor binding protein 3. The study was approved by the Independent Ethics Committee and the Scientific Council of the Menoufia University, Egypt. Thirty patients with ALL and thirty survivors who were diagnosed with ALL but completely recovered were enrolled in this study. Sex and age matched normal controls while full history was taken. Patients and survivors were examined for anthropometric measurement. Laboratory including serum IGFBP3and dual-energy x-ray absorptiometry was done for all. It has been found out that patients and survivors showed a markedly lower BMD than normal population but no history of fracture was found in survivors. In this study, the prevalence of low BMD is 26/30 (86.6%) patients and 25/30 (83.3%) survivors. Also, there was a statistically significant decrease of DEXA scan measures in patients and survivors groups than the control group with a statistically significant decrease in both BMD and Z- score measures in patients and survivors groups than control group. Patients and long-term survivors of childhood ALL are at risk for morbidity associated with low BMD. They may benefit from interventions to optimize bone health as they age. 

Об авторах

S. Ragab
Menoufia University


B. Montaser
Menoufia University


N. El-Ashmawy
Menoufia University


M. El-Hawy
Menoufia University

Pediatrics Department, Faculty of Medicine, 

Shebin el Kom, 32511 Menoufia

Список литературы

1. Seiter K., Sarkodee-Adoo C., Talavera F., Sacher R.A., Besa E.C., eds. Acute Lymphoblastic Leukemia. Medscape Reference. WebMD. Retrieved 17 April 2014.

2. Lin J.T., Lane J.M. Osteoporosis: a review. Clin Orthop Relat Res 2004; 425: 126–34.

3. NIH Consensus Development Panel on Osteoporosis. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–95.

4. Haddy T.B., Adde M.A., McCalla J. Late effects in longterm survivors of highgrade non-Hodgkin’s lymphomas. J Clin Oncol 1998; 16: 2070–9.

5. Kishi S., Griener J., Cheng С., Das S., Cook E.H., Pei D., et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21 (16): 3084–91.

6. Pui C.H., Sandlund J.T., Pei D. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104 (9): 2690–6.

7. ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 2004; 7: 17–26.

8. Frank R., Horacio P., Linda D.M., Raoul H.E., Richard C., Henderson C.M., et al. Fracture Prediction and the Definition of Osteoporosis in Children and Adolescents: The ISCD Pediatric Offi cial Positions. J Clin Densitom 2007; 1: 22–8.

9. Lewiecki E.M., Baim S., Binkley N., Bilezikian J.P., Kendler D.L. Report of the International Society for Clinica Densitometry 2007 Adult Position Development Conference and Official Positions. South Med J 2008: 101: 735–9.

10. Muszynska-Roslan K., Panasiuk A., Latoch E., Krawczuk-Rybak M., Konstantynowicz J. Little evidence of a low bone mass in acute lymphoblastic leukemia survivors. J Clin Densitom 2012; 15: 108–15.

11. Kang M.J., Lim J.S. Bone mineral density deficits in childhood cancer survivors: Pathophysiology, prevalence, screening, and management. Korean J Pediatr 2013; 56 (2): 60–7.

12. Kaste S.C., Jones-Wallace D., Rose S.R., Boyett J.M., Lustig R.H., Rivera G.K., et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001; 15: 728–34.

13. Hoorweg-Nijman J.J.G., Kardos G., Roost J.C. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukemia. Clin Endocrinol 1999; 50: 237–44.

14. Van der Sluis I.M., van den HeuvelEibrink M.M., Hahlen K., Krenning E.P., de Muinck Keizer-Schrama S.M. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 2000; 35: 415–20.

15. Reisi N., Iravani P., Raeissi P., Kelishadi R. Vitamin D and Bone Minerals Status in the Long-term Survivors of Childhood Acute Lymphoblastic Leukemia. Int J Prev Med 2015; 6: 87.

16. Sebestyen J.F., Srivastava T., Alon U.S. Bisphosphonates use in children. Clin Pediatr (Phila) 2012; 51: 1011–24.

17. Pfeilschifter J., Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570–93.


Для цитирования:

Ragab S., Montaser B., El-Ashmawy N., El-Hawy M. Bone changes during and after treatment of childhood acute lymphoblastic leukaemia. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021;20(1):54-57.

For citation:

Ragab S., Montaser B., El-Ashmawy N., El-Hawy M. Bone changes during and after treatment of childhood acute lymphoblastic leukaemia. Pediatric Hematology/Oncology and Immunopathology. 2021;20(1):54-57. (In Russ.)

Просмотров: 554

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.